GHRP-2
Phase II TrialsAlso known as: Pralmorelin, KP 102, Growth Hormone Releasing Peptide-2
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Muscle Recovery & Repair
- Growth Hormone Regulation
- Fat Loss & Metabolism
Acts as a ghrelin mimetic and GHSR-1a agonist, stimulating GH release from the anterior pituitary. Research indicates it also suppresses somatostatin release, amplifying GH pulses. Produces some stimulation of cortisol and prolactin in addition to GH.
Has been studied in multiple Phase II clinical trials. Not FDA-approved for general use. Approved in Japan for GH deficiency diagnosis. May elevate cortisol and prolactin.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha DK et al. (2020). Translational Andrology and Urology.DOI: 10.21037/tau.2019.11.30
Want to learn more?
Ask Research Chat about GHRP-2Half-Life
~30 minutes
Administration
subcutaneous injection, intravenous (diagnostic use)
Legal Status (US)
Research chemical in the US. Not FDA-approved. Approved diagnostically in Japan (as pralmorelin).
141 indexed research passages
Related Peptides
Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.
IGF-1 (insulin-like growth factor 1) is an endogenous polypeptide hormone critical for growth, development, and metabolic homeostasis. It is produced primarily in the liver in response to GH signaling and acts through IGF-1 receptors on virtually all tissues. Recombinant IGF-1 (mecasermin) is FDA-approved for children with severe primary IGF-1 deficiency.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in multiple countries including China, Japan, and the EU for the management of anemia associated with chronic kidney disease. It stimulates endogenous erythropoietin production by stabilizing HIF-alpha proteins.